Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 195
- Registration Number
- NCT04304209
- Locations
- 🇨🇳
Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 162
- Registration Number
- NCT04304352
- Locations
- 🇮🇹
European Institute of Oncology, Milan, Italy
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 25
- Registration Number
- NCT04301557
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 550
- Registration Number
- NCT04302441
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 178
- Registration Number
- NCT04296162
- Locations
- 🇨🇳
Zhi-Ming Shao, Shanghai, China
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery
- Conditions
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT04295317
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04281576
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 71
- Registration Number
- NCT04276493
- Locations
- 🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 4
- Registration Number
- NCT04274933
- Locations
- 🇺🇸
Greenville Health System Cance /ID# 216059, Greenville, South Carolina, United States
🇩🇪Universitaetsklinik Heidelberg /ID# 214679, Heidelberg, Baden-Wuerttemberg, Germany
🇵🇷GCM Medical Group PSC - Hato Rey /ID# 216904, San Juan, Puerto Rico
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 55
- Registration Number
- NCT04262687
- Locations
- 🇫🇷
Chu - Hôpital Saint Antoine, Paris, France
🇫🇷Privé - Cac - Institut Gustave Roussy, Villejuif, France
🇫🇷Privé - Cac - Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.